[1]
|
武东, 汪晓娟, 汪小五, 等. 104例住院患者药源性血小板减少症不良反应报告分析[J]. 中国医院药学杂志, 2019, 39(17): 1766-1771.
|
[2]
|
Warkentin, T.E., Sheppard, J.A., Horsewood, P., et al. (2000) Impact of the Patient Population on the Risk for Heparin-induced Thrombocytopenia. Blood, 96, 1703-1708.
https://doi.org/10.1182/blood.V96.5.1703.h8001703_1703_1708
|
[3]
|
Shen, Y.-M., Heather, W. and Stephen, B. (2018) Evaluating Thrombocytopenia during Heparin Therapy. JAMA, 319, 497. https://doi.org/10.1001/jama.2017.21898
|
[4]
|
郑永威, 袁榴娣. 肝素诱导性血小板减少症的研究进展[J]. 东南大学学报(医学版), 2014, 33(6): 815-819.
|
[5]
|
雷迁, 陈雷. 肝素/血小板因子4抗体与肝素诱导的血小板减少症[J]. 中国实验血液学杂志, 2008(2): 457-460.
|
[6]
|
Rauova, L., Arepally, G., Poncz, M., et al. (2018) Molecular and Cellular Pathogenesis of Heparin-Induced Thrombocytopenia (HIT). Autoimmunity Reviews, 17, 1046-1052. https://doi.org/10.1016/j.autrev.2018.05.003
|
[7]
|
曹磊, 谭颖, 吕继成, 等. 肝素诱导的血小板减少症[J]. 中国血液净化, 2009, 8(3): 163-166.
|
[8]
|
范庆坤, 张真路. 如何面对肝素诱导血小板减少症诊断的困惑[J]. 中华检验医学杂志, 2019, 42(4): 227-231.
|
[9]
|
门剑龙, 任静. 肝素诱导的血小板减少症的实验室诊断进展[J]. 中华检验医学杂志, 2016, 39(10): 795-800.
|
[10]
|
Warkentin, T.E. (2012) HITlights: A Career Perspective on Heparin-Induced Thrombocytopenia. American Journal of Hematology, 87, S92-S99. https://doi.org/10.1002/ajh.23127
|
[11]
|
Cohen, R.A., Castellano, M. and Garcia, C.A. (2012) Heparin Induced Thrombocytopenia: Case Presentation and Review. Journal of Clinical Medicine Research, 4, 68-72. https://doi.org/10.4021/jocmr751w
|
[12]
|
Dasararaju, R., Singh, N. and Mehta, A. (2013) Heparin Induced Thrombocytopenia: Review. Expert Review of Hematology, 6, 419-428. https://doi.org/10.1586/17474086.2013.814446
|
[13]
|
Cuker, A., Rux, A.H., Hinds, J.L., et al. (2013) Novel Diagnostic Assays for Heparin-Induced Thrombocytopenia. Blood, 121, 3727-3732. https://doi.org/10.1182/blood-2013-01-479576
|
[14]
|
Cuker, A., Gimotty, P.A., Crowther, M.A., et al. (2012) Predictive Value of the 4Ts Scoring System for Heparin-Induced Thrombocytopenia: A Systematic Review and Meta-Analysis. Blood, 120, 4160-4167.
https://doi.org/10.1182/blood-2012-07-443051
|
[15]
|
Joseph, L., Gomes, M.P.V., Al, S.F., et al. (2015) External Validation of the HIT Expert Probability (HEP) Score. Thrombosis and Haemostasis, 113, 633-640. https://doi.org/10.1160/TH14-05-0472
|
[16]
|
Pishko, A.M., Fardin, S., Lefler, D.S., et al. (2018) Prospective Comparison of the Hep Score and 4ts Score for the Diagnosis of Heparin-Induced Thrombocytopenia. Blood Advances, 2, 3155-3162.
https://doi.org/10.1182/bloodadvances.2018023077
|
[17]
|
Lillo-Le, L.A., Boutouyrie, P., Alhenc-Gelas, M., et al. (2004) Diagnostic Score for Heparin-Induced Thrombocytopenia after Cardiopulmonary Bypass. Journal of Thrombosis and Haemostasis, 2, 1882-1888.
https://doi.org/10.1111/j.1538-7836.2004.00949.x
|
[18]
|
Compton, F.B., Alrabeh, R., Nguyen, L.Q., et al. (2018) Pifa Pluss P4 Assay for Screening of Heparin-Induced Throm- bocytopenia. Laboratory Medicine, 50, 73-77. https://doi.org/10.1093/labmed/lmy048
|
[19]
|
周福硕, 黄凌瑾, 王锷, 等. 心脏手术患者围术期肝素诱导的血小板减少症[J]. 中南大学学报(医学版), 2015, 40(7): 790-796.
|
[20]
|
中国医师协会心血管内科医师分会血栓防治专业委员会与编辑委员会. 肝素诱导的血小板减少症中国专家共识(2017) [J]. 中华医学杂志, 2018, 98(6): 408-417.
|
[21]
|
于坤, 梁碧霞, 刘明政, 等. 肝素诱导的血小板减少症患者心脏外科手术期间抗凝治疗[J]. 中国体外循环杂志, 2018, 16(5): 297-301.
|
[22]
|
张明哲, 姚允泰, 李立环. 心脏手术患者肝素诱导血小板减少症[J]. 中国体外循环杂志, 2018, 16(5): 293-296, 311.
|
[23]
|
冯湧. 新一代抗凝血药阿加曲班的临床应用进展[J]. 医学信息, 2018, 31(2): 43-45.
|
[24]
|
Nutescu, E.A., Shapiro, N.L. and Chevalier, A. (2007) New Anticoagulant Agents: Direct Thrombin Inhibitors. Cardiology Clinics, 26, 169-187. https://doi.org/10.1016/j.ccl.2007.12.005
|
[25]
|
Zhou, P., Yin, J.-X., Tao, H.-L., et al. (2020) Pathogenesis and Management of Heparin-Induced Thrombocytopenia and Thrombosis. Clinica Chimica Acta, 504, 73-80. https://doi.org/10.1016/j.cca.2020.02.002
|
[26]
|
伍雪峰, 金至赓, 赖斌, 刘惠亮. 急性冠脉综合征患者经皮冠状动脉介入术中比伐卢定的研究进展[J]. 中华灾害救援医学, 2017, 5(2): 101-105.
|
[27]
|
晋辉, 邱翠婷, 刘静, 等. 比较阿加曲班和比伐卢定在高出血风险且肝素诱导的血小板减少症-IgG抗体阳性的ST段抬高型心肌梗死患者急诊经皮冠状动脉介入治疗中的抗凝疗效[J]. 中国循环杂志, 2019, 34(6): 545-551.
|
[28]
|
Marc, S., Julia, S., Jan, B.-W., et al. (2017) Use of Fondaparinux Off-Label or Approved Anticoagulants for Management of Heparin-Induced Thrombocytopenia. Journal of the American College of Cardiology, 70, 2636-2648.
https://doi.org/10.1016/j.jacc.2017.09.1099
|
[29]
|
Poudel, Ghimire, Dhital, et al. (2017) Spontaneous Hit Syndrome Post-Knee Replacement Surgery with Delayed Recovery of Thrombocytopenia: A Case Report and Literature Review. Platelets, 28, 614-620.
https://doi.org/10.1080/09537104.2017.1366973
|
[30]
|
Tvito, A., Bakchoul, T., Rowe, J.M., et al. (2015) Severe and Persistent Heparin-Induced Thrombocytopenia Despite Fondaparinux Treatment. American Journal of Hematology, 90, 675-678. https://doi.org/10.1002/ajh.23971
|
[31]
|
Aryal, M.R., Gosain, R., Donato, A., et al. (2020) Effectiveness of Intravenous Immunoglobulin Use in Heparin-Induced Thrombocytopenia. Blood Coagulation & Fibrinolysis, 31, 287-292. https://doi.org/10.1097/MBC.0000000000000918
|